Quintrio
Home

Stock overview

Legend Biotech Corporation American Depositary Shares

LEGN

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Last trade $16.28
Day change +$0.29 (+1.81%)
Day range $15.76 – $16.47
Volume 2,064,212
Market cap $3.10B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for LEGN.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for LEGN.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Why Is Legend Biotech Stock Falling Thursday?

Legend Biotech (LEGN) stock fell 7.52% in premarket trading Thursday after the cell therapy company announced an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million. The decline comes despite the company's strong market position and analyst Buy rating with a $58.57 price target, though recent earnings showed a wider-than-expected loss and revenue slightly below consensus.

GlobeNewswire Inc.

Legend Biotech Corporation Announces Pricing of Public Offering

Legend Biotech Corporation announced the pricing of an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million in gross proceeds. The offering is expected to close on June 23, 2026, with Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities serving as joint book-running managers.

GlobeNewswire Inc.

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Legend Biotech announced positive Phase 1 clinical data for LB2501, an investigational in vivo CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy achieved 100% objective response rate and 83.3% complete response rate at the higher dose level following a single infusion without lymphodepletion, with a favorable safety profile showing no dose-limiting toxicities, serious adverse events, or ICANS.

The Motley Fool

Why Legend Biotech Stock Crushed the Market on Monday

Legend Biotech (LEGN) surged 18% on Monday following bullish analyst updates from H.C. Wainwright and RBC Capital. The rally was partly inspired by Eli Lilly's $7 billion acquisition of Kelonia Therapeutics, a CAR-T therapy developer similar to Legend. Analysts highlighted Legend's promising pipeline programs, including encouraging progress on its CD19/CD20 dual-targeted therapy.

The Motley Fool

Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares

Suvretta Capital Management sold nearly 1.1 million shares of Arcutis Biotherapeutics (ARQT) during Q3, reducing its position by $35.78 million. Despite the sale, ARQT remains the fund's largest holding worth $197.51 million. The stock has doubled in value over the past year, significantly outperforming the S&P 500. The sale appears to be a risk management decision following the dramatic stock appreciation rather than a loss of conviction in the company's fundamentals.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.